Vertex Pharmaceuticals Inc VRTX:NASDAQ

Last Price$184.94NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/16/19

Today's Change+3.82(2.11%)
Bid (Size)$169.01 (1)
Ask (Size)$185.01 (21)
Day Low / High$180.84 - 185.75
Volume1.3 M
 

View Biotechnology IndustryPeer Comparison as of 08/16/2019

 

Vertex Pharmaceuticals Inc ( NASDAQ )

Price: $184.94
Change: +3.82 (2.11%)
Volume: 1.3 M
4:00PM ET 8/16/2019
 
 

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A
N/A
 
 

Biogen Inc ( NASDAQ )

Price: $231.68
Change: +4.05 (1.78%)
Volume: 1.1 M
3:59PM ET 8/16/2019
 
 

Illumina Inc ( NASDAQ )

Price: $286.17
Change: +1.40 (0.49%)
Volume: 926.7 K
3:59PM ET 8/16/2019
 
 

Regeneron Pharmaceuticals Inc ( NASDAQ )

Price: $296.85
Change: +3.74 (1.28%)
Volume: 742.6 K
4:00PM ET 8/16/2019
 

Read more news Recent News

Moderna Surges 7% on Pipeline Update, Further Collaboration With Vertex; Q2 Revenue Lower Than Expected
3:33PM ET 8/07/2019 MT Newswires

Moderna (MRNA) shares rose 7% in afternoon trade Wednesday after sharing a pipeline update and announced the extension of its agreement with Vertex (VRTX)....

Analysts' Scale Up Vertex Pharmaceuticals' 2019, 2020 Earnings Estimates
12:56PM ET 8/03/2019 MT Newswires

Vertex Pharmaceuticals Inc's (NASDAQ:VRTX, Recent Price: 178.39) full year forecasted earnings estimates for 2019 and 2020 have been increased. The...

Analysts' Increase Vertex Pharmaceuticals' Q3, 2019, 2020 Earnings Estimates
11:36AM ET 8/02/2019 MT Newswires

Q3, 2019, and 2020`s consensus estimates for Vertex Pharmaceuticals Inc (NASDAQ:VRTX, Recent Price: 179.29) have been revised upward. The Q3 earnings...

Equities Sink After Trump Announces Tariffs on $300 Billion of Chinese Goods
4:35PM ET 8/01/2019 MT Newswires

Stocks slumped Wednesday after President Donald Trump said the US would impose a 10% tariff on $300 billion of Chinese goods. The market was higher for...

Company Profile

Business DescriptionVertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA. View company web site for more details
Address50 Northern Avenue
Boston, Massachusetts 02210
Phone+1.617.341.6100
Number of Employees2,500
Recent SEC Filing08/15/20194
Chairman, President & Chief Executive OfficerJeffrey M. Leiden
Chief Financial Officer & Executive Vice PresidentCharles F. Wagner
Chief Scientific Officer & EVP-Global ResearchDavid Matthew Altshuler
Chief Medical Officer & Executive Vice PresidentReshma Kewalramani

Company Highlights

Price Open$183.08
Previous Close$181.12
52 Week Range$151.80 - 195.81
Market Capitalization$47.5 B
Shares Outstanding257.0 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement10/23/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings21.68
Earnings per Share$8.44
Beta vs. S&P 500N/A
Revenue$3.0 B
Net Profit Margin64.55%
Return on Equity51.71%

Analyst Ratings as of 08/09/2019

Buy
16
Overweight
1
Hold
7
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset